PortfoliosLab logo
PortfoliosLab logo
Tools
Portfolios
Screeners
Discussions
Penumbra, Inc. (PEN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Penumbra, Inc. (PEN)

Equity · Currency in USD · Last updated Apr 26, 2025

Company Info

ISIN

US70975L1070

CUSIP

70975L107

Sector

Healthcare

Industry

Medical Devices

IPO Date

Sep 18, 2015

Highlights

Market Cap

$11.55B

EPS (TTM)

$1.07

PE Ratio

278.74

PEG Ratio

-62.27

Total Revenue (TTM)

$1.24B

Gross Profit (TTM)

$787.25M

EBITDA (TTM)

$63.79M

Year Range

$148.00 - $310.00

Target Price

$318.29

Short %

5.45%

Short Ratio

3.57

Share Price Chart

Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Popular comparisons:
PEN vs. ELF PEN vs. MEDP PEN vs. PODD PEN vs. LLY PEN vs. SPY PEN vs. VOO PEN vs. BSX PEN vs. QYLD PEN vs. QQQ
Popular comparisons:
PEN vs. ELF PEN vs. MEDP PEN vs. PODD PEN vs. LLY PEN vs. SPY PEN vs. VOO PEN vs. BSX PEN vs. QYLD PEN vs. QQQ

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Penumbra, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

200.00%300.00%400.00%500.00%600.00%NovemberDecember2025FebruaryMarchApril
625.86%
182.18%
PEN (Penumbra, Inc.)
Benchmark (^GSPC)

Returns By Period

Penumbra, Inc. had a return of 26.23% year-to-date (YTD) and 45.88% in the last 12 months.

PEN

YTD

26.23%

1M

8.95%

6M

46.44%

1Y

45.88%

5Y*

9.57%

10Y*

N/A

^GSPC (Benchmark)

YTD

-6.06%

1M

-3.27%

6M

-4.87%

1Y

9.44%

5Y*

14.30%

10Y*

10.11%

*Annualized

Monthly Returns

The table below presents the monthly returns of PEN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.

JanFebMarAprMayJunJulAugSepOctNovDecTotal
202512.42%6.92%-6.32%12.11%26.23%
20240.26%-6.85%-5.00%-11.97%-3.56%-5.01%-7.16%21.08%-3.96%17.79%6.66%-2.72%-5.59%
202312.56%3.83%7.19%1.95%8.17%11.95%-11.83%-12.81%-8.54%-20.98%16.19%13.26%13.07%
2022-21.34%-1.89%0.18%-22.32%-14.86%-15.25%11.93%17.79%15.49%-9.56%22.18%6.18%-22.57%
202149.19%8.94%-4.87%13.09%-18.59%10.02%-2.86%3.28%-3.07%3.77%-11.17%16.96%64.18%
20206.81%-5.47%-2.73%9.91%-2.76%3.71%24.10%-5.75%-7.06%34.29%-14.99%-21.14%6.53%
201919.08%-8.14%9.98%-8.51%6.10%12.12%4.75%-13.16%-7.60%15.97%13.43%-7.15%34.43%
20185.84%8.63%6.89%7.52%29.39%-14.14%2.97%-2.39%7.81%-9.15%2.37%-12.23%29.86%
201712.15%7.34%8.66%2.40%-3.04%5.91%-6.95%5.33%5.00%11.35%4.72%-10.64%47.49%
2016-20.46%8.93%-1.33%18.48%-3.14%12.71%14.81%3.29%7.70%-13.21%-6.14%3.07%18.57%
2015-2.91%-7.66%35.89%6.94%30.29%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 84, PEN is among the top 16% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.

The Risk-Adjusted Performance Rank of PEN is 8484
Overall Rank
The Sharpe Ratio Rank of PEN is 8787
Sharpe Ratio Rank
The Sortino Ratio Rank of PEN is 8484
Sortino Ratio Rank
The Omega Ratio Rank of PEN is 8080
Omega Ratio Rank
The Calmar Ratio Rank of PEN is 8383
Calmar Ratio Rank
The Martin Ratio Rank of PEN is 8888
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Penumbra, Inc. (PEN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.

The chart of Sharpe ratio for PEN, currently valued at 1.14, compared to the broader market-2.00-1.000.001.002.003.00
PEN: 1.14
^GSPC: 0.46
The chart of Sortino ratio for PEN, currently valued at 1.85, compared to the broader market-6.00-4.00-2.000.002.004.00
PEN: 1.85
^GSPC: 0.77
The chart of Omega ratio for PEN, currently valued at 1.22, compared to the broader market0.501.001.502.00
PEN: 1.22
^GSPC: 1.11
The chart of Calmar ratio for PEN, currently valued at 0.87, compared to the broader market0.001.002.003.004.005.00
PEN: 0.87
^GSPC: 0.47
The chart of Martin ratio for PEN, currently valued at 5.20, compared to the broader market-5.000.005.0010.0015.0020.00
PEN: 5.20
^GSPC: 1.94

The current Penumbra, Inc. Sharpe ratio is 1.14. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Penumbra, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.

Rolling 12-month Sharpe Ratio0.001.002.003.00NovemberDecember2025FebruaryMarchApril
1.14
0.46
PEN (Penumbra, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History

Penumbra, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

-40.00%-30.00%-20.00%-10.00%0.00%NovemberDecember2025FebruaryMarchApril
-12.87%
-10.07%
PEN (Penumbra, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Penumbra, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Penumbra, Inc. was 62.64%, occurring on Jun 16, 2022. Recovery took 224 trading sessions.

The current Penumbra, Inc. drawdown is 12.87%.

Depth

Start

To Bottom

Bottom

To Recover

End

Total

-62.64%Apr 29, 2021287Jun 16, 2022224May 9, 2023511
-52.44%Jul 3, 2023277Aug 7, 2024———
-35.86%Nov 13, 202023Dec 16, 202036Feb 9, 202159
-35.83%Feb 20, 202023Mar 23, 202074Jul 8, 202097
-31.65%Jun 7, 2018139Dec 24, 2018118Jun 14, 2019257

Volatility

Volatility Chart

The current Penumbra, Inc. volatility is 13.06%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.

0.00%5.00%10.00%15.00%NovemberDecember2025FebruaryMarchApril
13.06%
14.23%
PEN (Penumbra, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Penumbra, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Annual
Quarterly
0.0

Valuation

The Valuation section provides an overview of how Penumbra, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.

PE Ratio
20.040.060.080.0100.0
PEN: 278.7
The chart displays the Price-to-Earnings (P/E) ratio for PEN, comparing it with other companies in the Medical Devices industry. Currently, PEN has a P/E ratio of 278.7. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
2.04.06.08.010.0
PEN: -62.3
The chart shows the Price/Earnings to Growth (PEG) ratio for PEN compared to other companies in the Medical Devices industry. PEN currently has a PEG ratio of -62.3. This PEG ratio is negative, which typically signals that the company's earnings are expected to decline. A negative PEG is not considered meaningful for valuation purposes.
PS Ratio
2.04.06.08.010.0
PEN: 9.3
This chart shows the Price-to-Sales (P/S) ratio for PEN relative to other companies in the Medical Devices industry. Currently, PEN has a P/S ratio of 9.3. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
2.04.06.08.010.0
PEN: 9.5
The chart illustrates the Price-to-Book (P/B) ratio for PEN in comparison with other companies in the Medical Devices industry. Currently, PEN has a P/B value of 9.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement

TTM
Revenue
—

Total Revenue

—

Cost Of Revenue

—

Gross Profit

—
Operating Expenses
—

Selling, General & Admin Expenses

—

R&D Expenses

—

Depreciation And Amortization

—

Total Operating Expenses

—
Income
—

Income Before Tax

—

Operating Income

—

EBITDA

—

EBIT

—

Earnings From Continuing Operations

—

Net Income

—

Income Tax Expense

—

Other Non-Operating Income (Expenses)

—

Extraordinary Items

—

Discontinued Operations

—

Effect Of Accounting Charges

—

Non Recurring

—

Minority Interest

—

Other Items

—

Interest Income

—

Interest Expense

—

Net Interest Income

—
Values in undefined except per share items